Cohance Lifesciences Limited (BOM:543064)
India · Delayed Price · Currency is INR 476.80
-1.20 (-0.25%)
At close: Oct 28, 2026
Cohance Lifesciences Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 182,135 | 115,325 | 293,004 | 172,366 | 120,256 | 157,436 | |
Market Cap Growth | -45.68% | -60.64% | 69.99% | 43.33% | -23.61% | 24.49% |
Enterprise Value | 184,106 | 117,196 | 287,341 | 165,176 | 117,048 | 156,449 |
Last Close Price | 476.80 | 301.90 | 1159.80 | 676.60 | 472.70 | 608.03 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 171.45 | 64.35 | 60.12 | 57.40 | 29.24 | 34.69 |
PS Ratio | 8.51 | 5.08 | 11.23 | 16.40 | 8.97 | 11.93 |
PB Ratio | 4.52 | 2.86 | 7.73 | 8.40 | 6.93 | 10.31 |
P/TBV Ratio | 7.20 | 4.56 | 12.72 | 8.67 | 7.19 | 10.32 |
P/FCF Ratio | 122.70 | 77.69 | 82.18 | 51.78 | 70.21 | 61.79 |
P/OCF Ratio | 49.45 | 31.31 | 43.51 | 44.80 | 26.30 | 47.71 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 8.60 | 5.17 | 11.02 | 15.71 | 8.73 | 11.85 |
EV/EBITDA Ratio | 58.10 | 29.97 | 35.78 | 40.39 | 20.44 | 27.00 |
EV/EBIT Ratio | 147.98 | 48.57 | 43.50 | 46.61 | 22.25 | 28.89 |
EV/FCF Ratio | 124.03 | 78.95 | 80.59 | 49.62 | 68.34 | 61.40 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.10 | 0.10 | 0.13 | 0.03 | 0.04 | 0.06 |
Debt / EBITDA Ratio | 1.26 | 0.94 | 0.59 | 0.16 | 0.12 | 0.17 |
Debt / FCF Ratio | - | 2.70 | 1.36 | 0.20 | 0.41 | 0.38 |
Net Debt / Equity Ratio | 0.02 | 0.02 | 0.05 | -0.37 | -0.24 | -0.28 |
Net Debt / EBITDA Ratio | 0.24 | 0.21 | 0.23 | -1.85 | -0.72 | -0.74 |
Net Debt / FCF Ratio | - | 0.54 | 0.53 | -2.27 | -2.41 | -1.68 |
Asset Turnover | - | 0.41 | 0.67 | 0.50 | 0.71 | 0.80 |
Inventory Turnover | - | 1.56 | 2.69 | 1.32 | 1.87 | 2.24 |
Quick Ratio | - | 1.83 | 1.76 | 8.61 | 4.17 | 3.85 |
Current Ratio | - | 2.83 | 2.54 | 10.68 | 6.37 | 5.36 |
Return on Equity (ROE) | - | 3.84% | 16.57% | 15.86% | 25.21% | 33.52% |
Return on Assets (ROA) | - | 2.69% | 10.67% | 10.50% | 17.33% | 20.49% |
Return on Invested Capital (ROIC) | 1.75% | 4.32% | 18.87% | 20.05% | 31.95% | 32.95% |
Return on Capital Employed (ROCE) | - | 4.70% | 13.80% | 16.60% | 29.10% | 33.40% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 27, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 0.58% | 1.55% | 1.66% | 1.74% | 3.42% | 2.88% |
FCF Yield | 0.81% | 1.29% | 1.22% | 1.93% | 1.42% | 1.62% |
Dividend Yield | - | - | - | - | 0.64% | 0.32% |
Payout Ratio | - | - | - | - | 49.52% | 22.44% |
Buyback Yield / Dilution | - | 0.21% | -50.73% | - | 0.00% | 0.00% |
Total Shareholder Return | - | 0.21% | -50.73% | - | 0.64% | 0.32% |